11 Nov Wound Management Technologies Inc. solicits technology and development partners to leverage infrastructure for biotech and genetics
The BioPharma Management Technologies Division of Wound Management Technologies, Inc., (WNDM) will search for partners to aid in leveraging its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields.
Wound Management Technologies, Inc is a provider of specialty medical products and advanced biotechnology solutions. The recent acquisition of Resorbable Orthopedics LLC with its patented technologies, including a resorbable bone wax and a delivery system for orthopedic bone void fillers, was WNDM’s first step to extend its product reach and incubator philosophy beyond Wound Care Innovation and its patented, activated form of collagen found in CellerateRXÂ® products.
“Some of the most important developments in biotechnology and medical science have their origin at academic institutions and the startups that spring from them,” stated Scott Haire, CEO of WNDM. “For example, Stem Cell Technology first came on the scene through the efforts of James Thomson in 1998 at the University of Wisconsin. James Thomson is the scientist who was the first to recover embryonic stem cells from human embryos through his work at the University Of Wisconsin School Of Medicine. The companies that are the first to capitalize on these types of advances gain a huge advantage for their shareholders.”
WNDM has been conducting extended research studies on its existing products to seek out these types of advantages. It was recently observed at the University of Colorado and presented at a key worldwide symposium that WNDM’s own CellerateRx has been shown to possibly influence biological factors important to wound healing beyond the obvious maintenance of the wound environment.